Renal cell adenocarcinoma
MONDO:0005549A carcinoma arising from the renal parenchyma. There is a strong correlation between cigarette smoking and the development of renal cell carcinoma. The clinical presentation includes : hematuria, flank pain and a palpable lumbar mass. A high percentage of renal cell carcinomas are diagnosed when an ultrasound is performed for other purposes. Radical nephrectomy is the standard intervention procedure. Renal cell carcinoma is generally considered to be resistant to radiation treatment and chemotherapy.
Also known as: renal cell carcinoma, RCC, adenocarcinoma of kidney, adenocarcinoma of the kidney, carcinoma, renal cell, malignant, kidney adenocarcinoma, renal cell adenocarcinoma, renal cell cancer
3016 clinical trials for this condition and its sub-types, 98 tagged with Renal cell adenocarcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Renal cell adenocarcinoma
-
Clear cell renal carcinoma 140 trials · 142 incl. sub-types
2 sub-types
-
Papillary renal cell carcinoma 26 trials · 28 incl. sub-types
1 sub-type
-
Childhood kidney cell carcinoma 21 trials
-
Sarcomatoid renal cell carcinoma 15 trials
-
Chromophobe renal cell carcinoma 13 trials
2 sub-types
-
Hereditary renal cell carcinoma 1 trial · 7 incl. sub-types
7 sub-types
- Hereditary clear cell renal cell carcinoma 4 trials
- PAX6-related ocular dysgenesis 0 trials · 2 incl. sub-types Sub-types →
- Hereditary papillary renal cell carcinoma 2 trials
- Adrenocortical carcinoma, hereditary 0 trials
- Aniridia 2 0 trials
- Aniridia 3 0 trials
- Renal cell carcinoma, Xp11-associated 0 trials
-
Tubulocystic renal cell carcinoma 0 trials
Most studied deeper sub-types
-
New drug cocktail targets rare, aggressive kidney cancer
Disease control CompletedThis phase II trial is testing whether combining the targeted drug ixazomib with two chemotherapy drugs (gemcitabine and doxorubicin) can shrink tumors or stop them from growing in patients with a rare and aggressive kidney cancer called renal medullary carcinoma. The study enrol…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New combo approach for kidney cancer shows promise in early trial
Disease control CompletedThis study tested a two-step treatment for medium-sized kidney tumors (4.1-7 cm). First, doctors blocked the tumor's blood supply, then froze it. The goal was to see if this approach is safe and works well. 25 adults with stage T1b kidney cancer took part. The main focus was on s…
Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Kidney cancer drugs fail to prevent recurrence after surgery
Disease control CompletedThis large phase 3 trial tested whether taking sorafenib or sunitinib after kidney cancer surgery could prevent the cancer from coming back. Nearly 2000 patients participated. Unfortunately, neither drug improved disease-free survival compared to a placebo, and they caused side e…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Real-World data shows promise for kidney cancer drug combo
Disease control CompletedThis completed study looked at how well avelumab (BAVENCIO) plus axitinib (INLYTA) works for advanced kidney cancer in everyday medical practice. Researchers tracked 105 patients across multiple EU countries to see survival rates at 12 and 24 months. The goal was to understand th…
Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New kidney cancer drug shows promise in early trial
Disease control CompletedThis early-stage trial tested a drug called belzutifan in 29 people with advanced clear cell kidney cancer that had worsened after other treatments. The main goal was to check safety and find the right dose. Participants took belzutifan pills daily, and researchers monitored side…
Phase 1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug cocktail aims to fight advanced cancers
Disease control CompletedThis early-phase study tested a daily combination of two oral drugs, axitinib and everolimus, in 19 people with advanced solid tumors, particularly kidney cancer. The main goal was to find the safest dose by monitoring side effects in the first month. Researchers also tracked how…
Phase 1 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Immunotherapy combo before kidney surgery shows promise in small trial
Disease control CompletedThis early-phase study tested two immunotherapy drugs (spartalizumab and canakinumab) given before surgery to 17 people with localized clear cell kidney cancer. The main goal was to see if this approach was safe and did not delay surgery. The study also looked at how the drugs af…
Early phase 1 • Sponsor: Columbia University • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Can a special MRI spot kidney cancer better?
Diagnosis CompletedThis study tested whether a special type of MRI, called perfusion MRI, can help doctors find and diagnose kidney tumors more accurately. 75 people with kidney cancer or suspected kidney tumors took part. The goal was to see if this imaging method could predict tumor type and how …
Sponsor: Rutgers, The State University of New Jersey • Aim: Diagnosis
Last updated Jun 27, 2026 13:01 UTC
-
Kidney cancer patients in Real-World clinics get immunotherapy: does it work?
Knowledge-focused CompletedThis study followed 623 adults in France with advanced kidney cancer who were starting treatment with the immunotherapy drugs nivolumab (with or without ipilimumab) for the first time. Unlike a clinical trial, this was an observational study that simply tracked what happened in e…
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New biomarker may predict which cancer drugs work best
Knowledge-focused CompletedThis completed study tested whether a new biomarker called 'mass response' can predict how well a cancer therapy will work. Researchers collected tumor cells from 72 patients with various cancers through fluid drainage or biopsies. The goal was to see if this biomarker could guid…
Sponsor: Travera Inc • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Smart devices track cancer recovery at home
Knowledge-focused CompletedThis study tested whether using at-home monitoring devices (like a wristband pedometer, scale, and blood pressure cuff) can help improve care for cancer patients after they leave the hospital following surgery. 22 patients with various cancers participated. The goal was to see if…
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:02 UTC